Back to Search
Start Over
Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia
- Source :
- Leukemia & Lymphoma. 56:2326-2330
- Publication Year :
- 2015
- Publisher :
- Informa UK Limited, 2015.
-
Abstract
- The prognosis of refractory/relapsed acute myeloid leukemia (AML) remains poor. The complete response (CR) rate after relapse is around 25%, with 11% of patients still alive after 5 years. The efficacy and toxicity of fractionated gemtuzumab ozogamicin (fGO; 3 mg/m2, days 1, 4, 7) in combination with intensive chemotherapy were retrospectively evaluated in patients with refractory/relapsed AML. Thirty-six patients (median age 54 years) were included. European LeukemiaNet classification was as follows: favorable (n=6), intermediate-I (n=13), intermediate-II (n=8), adverse (n=9). Median CR duration was 7.16 months (1.63-96.8). The overall response rate was 38.8%, with CR in eight patients (22.2%) and CR with incomplete platelet recovery (CRp) in six patients (16.7%). Two-year overall survival was 26% (95% confidence interval [CI]: 12-42) and 2-year relapse free-survival was 18.5% (95% CI: 6.6-35.0). Salvage therapy with fractionated GO in patients with very high-risk disease produced a 38.8% response rate and may be considered as a bridge therapy to transplant.
- Subjects :
- Adult
Male
Cancer Research
medicine.medical_specialty
Adolescent
Gemtuzumab ozogamicin
Salvage therapy
Antibodies, Monoclonal, Humanized
Gastroenterology
Young Adult
European LeukemiaNet
Refractory
Recurrence
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Aged
Salvage Therapy
Response rate (survey)
business.industry
Remission Induction
Hematopoietic Stem Cell Transplantation
Myeloid leukemia
Hematology
Middle Aged
Prognosis
Gemtuzumab
Survival Analysis
Confidence interval
Surgery
Leukemia, Myeloid, Acute
Aminoglycosides
Treatment Outcome
Oncology
Toxicity
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 10292403 and 10428194
- Volume :
- 56
- Database :
- OpenAIRE
- Journal :
- Leukemia & Lymphoma
- Accession number :
- edsair.doi.dedup.....0e6e2358f6a68ee38ea48258823bb4e2
- Full Text :
- https://doi.org/10.3109/10428194.2014.986478